全文获取类型
收费全文 | 20390篇 |
免费 | 1220篇 |
国内免费 | 204篇 |
专业分类
耳鼻咽喉 | 165篇 |
儿科学 | 338篇 |
妇产科学 | 334篇 |
基础医学 | 2897篇 |
口腔科学 | 674篇 |
临床医学 | 1866篇 |
内科学 | 5351篇 |
皮肤病学 | 231篇 |
神经病学 | 2090篇 |
特种医学 | 709篇 |
外科学 | 2994篇 |
综合类 | 66篇 |
一般理论 | 3篇 |
预防医学 | 1018篇 |
眼科学 | 257篇 |
药学 | 1620篇 |
中国医学 | 69篇 |
肿瘤学 | 1132篇 |
出版年
2023年 | 132篇 |
2022年 | 339篇 |
2021年 | 576篇 |
2020年 | 403篇 |
2019年 | 512篇 |
2018年 | 629篇 |
2017年 | 458篇 |
2016年 | 523篇 |
2015年 | 599篇 |
2014年 | 798篇 |
2013年 | 969篇 |
2012年 | 1544篇 |
2011年 | 1587篇 |
2010年 | 878篇 |
2009年 | 788篇 |
2008年 | 1236篇 |
2007年 | 1327篇 |
2006年 | 1151篇 |
2005年 | 1216篇 |
2004年 | 1113篇 |
2003年 | 990篇 |
2002年 | 956篇 |
2001年 | 227篇 |
2000年 | 228篇 |
1999年 | 233篇 |
1998年 | 224篇 |
1997年 | 154篇 |
1996年 | 114篇 |
1995年 | 115篇 |
1994年 | 107篇 |
1993年 | 101篇 |
1992年 | 146篇 |
1991年 | 99篇 |
1990年 | 91篇 |
1989年 | 66篇 |
1988年 | 69篇 |
1987年 | 63篇 |
1986年 | 66篇 |
1985年 | 55篇 |
1984年 | 54篇 |
1983年 | 41篇 |
1982年 | 37篇 |
1981年 | 35篇 |
1980年 | 34篇 |
1978年 | 22篇 |
1973年 | 26篇 |
1971年 | 22篇 |
1970年 | 25篇 |
1925年 | 23篇 |
1922年 | 22篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
991.
Low molecular weight heparin improves healing of chronic venous ulcers especially in the elderly 下载免费PDF全文
Raffaele Serra Gianluca Buffone Vincenzo Molinari Rossella Montemurro Paolo Perri Domenico M Stillitano Bruno Amato Stefano de Franciscis 《International wound journal》2015,12(2):150-153
Venous ulcers are common, especially in the elderly, accounting for more than 50% of all lower extremity ulcers with important socioeconomic problems. Improving extracellular matrix functioning, by heparin administration, seems to be a way to support wound healing. A total of 284 patients with venous ulcers were recruited in a 4‐year period. All patients were subjected to the most appropriate treatment after considering their preference (compression therapy followed or not by vein surgery). Patients were randomised into two groups of 142 persons in each (group A and group B as cases and controls, respectively). Patients of group A, in addition to the basic treatment as described earlier, received administration of nadroparin 2850 IU/0.3 ml through subcutaneous injection once a day for 12 months, whereas group B patients received basic treatment alone. Healing was assessed by means of direct ulcer tracing with computerised planimetry. Group A showed a healing rate of 83·80% at 12 months, whereas that of group B was 60·56%. Results by age group surprisingly showed that the group of older patients took the most advantage from long‐term treatment with low molecular weight heparin; this group also had lowest recurrence rate. 相似文献
992.
Dearterialization of the liver causes intrahepatic cholestasis due to reduced bile transporter expression 总被引:1,自引:0,他引:1
Hoekstra H Tian Y Jochum W Stieger B Graf R Porte RJ Clavien PA 《Transplantation》2008,85(8):1159-1166
BACKGROUND: Bile duct injury after hepatic artery thrombosis (HAT) in liver transplantation is believed to be caused by ischemia predominantly. We aimed to define the involvement of bile secretory dysfunction in the pathogenesis of liver injury after HAT. METHODS: In a murine model, the main hepatic artery, the extrahepatic peribiliary plexus, or both arterial connections to the liver were interrupted (n=5 for each group). After 1, 14, or 28 days, hepatobiliary function was assessed by analysis of bile transporter expression, serum bile acids and bilirubin, and hepatic ATP content. In addition, cellular injury was assessed by light microscopy and biochemical markers. RESULTS: There were no signs of hepatobiliary dysfunction or injury in sham-operated animals or in mice with interruption of the hepatic artery or the extrahepatic peribiliary plexus alone. However, as early as 24 hr after complete dearterialization, bile transporter expression was significantly reduced and intrahepatic cholestasis started to progress the following weeks. Histologic studies at 28 days after complete dearterialization showed severe hepatobiliary injury. CONCLUSIONS: This study indicates that arterial blood supply is critical for normal bile secretion. Bile duct injury after complete arterial deprivation is preceded by a loss of bile secretory function and subsequent intrahepatic cholestasis. 相似文献
993.
Caillard S Pencreach E Braun L Marcellin L Jaegle ML Wolf P Parissiadis A Hannedouche T Gaub MP Moulin B 《Transplantation》2005,79(1):79-84
BACKGROUND: Posttransplant lymphoproliferative disorders (PTLD) occur in 0.5% to 2.5% of cases in renal-transplant recipients. Epstein-Barr virus (EBV) is usually detected in the tumor cells, suggesting a role for this virus as an agent of B-cell proliferation. It is unusual for patients receiving allografts from the same donor to develop PTLD simultaneously. METHODS: we describe two patients who received renal allografts from the same donor and developed PTLD simultaneously. The presence of EBV in both tumors was confirmed. In this report, the origin of tumor cells was determined by immunohistochemical human leukocyte antigen (HLA) typing and microsatellite analysis. Clonality was studied by immunoglobulin gene rearrangement analysis. RESULTS: Our results suggest that the tumor originated from donor cells in both patients but, because immunoglobulin gene rearrangements were different, this could mean that lymphoid cells proliferate independently in each recipient. CONCLUSIONS: We propose the following pathogenesis: immortalization of passenger B lymphocytes by EBV, proliferation of these cells, and development of PTLD by means of immunosuppression, antigenic stimulation, and HLA mismatch. 相似文献
994.
995.
Bruno Guedes Baldi Alexandre Todorovic Fabro Andreia Craveiro Franco Marília Helena C Machado Robson Aparecido Prudente Estefnia Thom Franco Sergio Ribeiro Marrone Simone Alves do Vale Talita Jacon Cezare Marcelo Padovani de Toledo Moraes Eloara Vieira Machado Ferreira Andr Luis Pereira Albuquerque Marcio Valente Yamada Sawamura Suzana Erico Tanni 《Jornal brasileiro de pneumologia》2022,48(3)
996.
997.
Michelangelo Mancuso Daniele Orsucci Corrado Angelini Enrico Bertini Valerio Carelli Giacomo Pietro Comi Maria Alice Donati Antonio Federico Carlo Minetti Maurizio Moggio Tiziana Mongini Filippo Maria Santorelli Serenella Servidei Paola Tonin Antonio Toscano Claudio Bruno Luca Bello Elena Caldarazzo Ienco Elena Cardaioli Michela Catteruccia Paola Da Pozzo Massimiliano Filosto Costanza Lamperti Isabella Moroni Olimpia Musumeci Elena Pegoraro Dario Ronchi Donato Sauchelli Mauro Scarpelli Monica Sciacco Maria Lucia Valentino Liliana Vercelli Massimo Zeviani Gabriele Siciliano 《Journal of neurology》2015,262(5):1301-1309
998.
Alessandro Pocai Paul E. Carrington Jennifer R. Adams Michael Wright George Eiermann Lan Zhu Xiaobing Du Aleksandr Petrov Michael E. Lassman Guoqiang Jiang Franklin Liu Corey Miller Laurie M. Tota Gaochao Zhou Xiaoping Zhang Michael M. Sountis Alessia Santoprete Elena Capito' Gary G. Chicchi Nancy Thornberry Elisabetta Bianchi Antonello Pessi Donald J. Marsh Ranabir SinhaRoy 《Diabetes》2009,58(10):2258-2266
OBJECTIVE
Oxyntomodulin (OXM) is a glucagon-like peptide 1 (GLP-1) receptor (GLP1R)/glucagon receptor (GCGR) dual agonist peptide that reduces body weight in obese subjects through increased energy expenditure and decreased energy intake. The metabolic effects of OXM have been attributed primarily to GLP1R agonism. We examined whether a long acting GLP1R/GCGR dual agonist peptide exerts metabolic effects in diet-induced obese mice that are distinct from those obtained with a GLP1R-selective agonist.RESEARCH DESIGN AND METHODS
We developed a protease-resistant dual GLP1R/GCGR agonist, DualAG, and a corresponding GLP1R-selective agonist, GLPAG, matched for GLP1R agonist potency and pharmacokinetics. The metabolic effects of these two peptides with respect to weight loss, caloric reduction, glucose control, and lipid lowering, were compared upon chronic dosing in diet-induced obese (DIO) mice. Acute studies in DIO mice revealed metabolic pathways that were modulated independent of weight loss. Studies in Glp1r−/− and Gcgr−/− mice enabled delineation of the contribution of GLP1R versus GCGR activation to the pharmacology of DualAG.RESULTS
Peptide DualAG exhibits superior weight loss, lipid-lowering activity, and antihyperglycemic efficacy comparable to GLPAG. Improvements in plasma metabolic parameters including insulin, leptin, and adiponectin were more pronounced upon chronic treatment with DualAG than with GLPAG. Dual receptor agonism also increased fatty acid oxidation and reduced hepatic steatosis in DIO mice. The antiobesity effects of DualAG require activation of both GLP1R and GCGR.CONCLUSIONS
Sustained GLP1R/GCGR dual agonism reverses obesity in DIO mice and is a novel therapeutic approach to the treatment of obesity.Obesity is an important risk factor for type 2 diabetes, and ∼90% of patients with type 2 diabetes are overweight or obese (1). Among new therapies for type 2 diabetes, peptidyl mimetics of the gut-derived incretin hormone glucagon-like peptide 1 (GLP-1) stimulate insulin biosynthesis and secretion in a glucose-dependent manner (2,3) and cause modest weight loss in type 2 diabetic patients. The glucose-lowering and antiobesity effects of incretin-based therapies for type 2 diabetes have prompted evaluation of the therapeutic potential of other glucagon-family peptides, in particular oxyntomodulin (OXM). The OXM peptide is generated by post-translational processing of preproglucagon in the gut and is secreted postprandially from l-cells of the jejuno-ileum together with other preproglucagon-derived peptides including GLP-1 (4,5). In rodents, OXM reduces food intake and body weight, increases energy expenditure, and improves glucose metabolism (6–8). A 4-week clinical study in obese subjects demonstrated that repeated subcutaneous administration of OXM was well tolerated and caused significant weight loss with a concomitant reduction in food intake (9). An increase in activity-related energy expenditure was also noted in a separate study involving short-term treatment with the peptide (10).OXM activates both, the GLP-1 receptor (GLP1R) and glucagon receptor (GCGR) in vitro, albeit with 10- to 100-fold reduced potency compared with the cognate ligands GLP-1 and glucagon, respectively (11–13). It has been proposed that OXM modulates glucose and energy homeostasis solely by GLP1R agonism, because its acute metabolic effects in rodents are abolished by coadministration of the GLP1R antagonist exendin(9–39) and are not observed in Glp1r−/− mice (7,8,14,15). Other aspects of OXM pharmacology, however, such as protective effects on murine islets and inhibition of gastric acid secretion appear to be independent of GLP1R signaling (14). In addition, pharmacological activation of GCGR by glucagon, a master regulator of fasting metabolism (16), decreases food intake in rodents and humans (17–19), suggesting a potential role for GCGR signaling in the pharmacology of OXM. Because both OXM and GLP-1 are labile in vivo (T1/2 ∼12 min and 2–3 min, respectively) (20,21) and are substrates for the cell surface protease dipeptidyl peptidase 4 (DPP-4) (22), we developed two long-acting DPP-4–resistant OXM analogs as pharmacological agents to better investigate the differential pharmacology and therapeutic potential of dual GLP1R/GCGR agonism versus GLP1R-selective agonism. Peptide DualAG exhibits in vitro GLP1R and GCGR agonist potency comparable to that of native OXM and is conjugated to cholesterol via a Cys sidechain at the C-terminus for improved pharmacokinetics. Peptide GLPAG differs from DualAG by only one residue (Gln3→Glu) and is an equipotent GLP1R agonist, but has no significant GCGR agonist or antagonist activity in vitro. The objective of this study was to leverage the matched GLP1R agonist potencies and pharmacokinetics of peptides DualAG and GLPAG in comparing the metabolic effects and therapeutic potential of a dual GLP1R/GCGR agonist with a GLP1R-selective agonist in a mouse model of obesity. 相似文献999.
David M Dohan Joseph Choukroun Antoine Diss Steve L Dohan Anthony J J Dohan Jaafar Mouhyi Bruno Gogly 《Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics》2006,101(3):e37-e44
Platelet-rich fibrin (PRF) belongs to a new generation of platelet concentrates geared to simplified preparation without biochemical blood handling. In this initial article, we describe the conceptual and technical evolution from fibrin glues to platelet concentrates. This retrospective analysis is necessary for the understanding of fibrin technologies and the evaluation of the biochemical properties of 3 generations of surgical additives, respectively fibrin adhesives, concentrated platelet-rich plasma (cPRP) and PRF. Indeed, the 3-dimensional fibrin architecture is deeply dependent on artificial clinical polymerization processes, such as massive bovine thrombin addition. Currently, the slow polymerization during PRF preparation seems to generate a fibrin network very similar to the natural one. Such a network leads to a more efficient cell migration and proliferation and thus cicatrization. 相似文献
1000.